EUVIMEDEUVIMED entdecken
Crossref

Integrating Genomics, Transcriptomics, and Organoid-Based Drug Testing for Precision Cancer Care

Integrative Biomedical Research · 2026

DOI: 10.25163/biomedical.10110907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Integrative Biomedical Research, 2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic profiling has reshaped oncology, yet only a minority of sequenced patients ever receive a molecularly matched therapy, and identical driver mutations often yield inconsistent clinical outcomes. This gap suggests that static DNA-level data alone cannot capture the dynamic, evolving biology of tumors. We synthesized real-world implementation cohorts, diagnostic-platform comparisons, biomarker-pathobiology data, and workforce-competency evidence drawn from recently published precision oncology literature, and we outline a prospective multi-omic pipeline — combining targeted DNA panels, transcriptomics, methylation and copy-number signatures, and patient-derived organoid drug screening — layered onto machine-learning fusion models. Across programs such as KOSMOS and the pediatric integrative-genomics cohort, actionable alterations were identified in 55–100% of patients, yet molecularly matched treatment was ultimately delivered to only 38–51% of cases. Transcriptomic and functional assays improved concordance between predicted and observed drug sensitivity, while copy-number and methylation signatures added prognostic information beyond single-nucleotide variants. Diagnostic-platform trade-offs (depth versus breadth), clonal hematopoiesis confounding in liquid biopsy, and demographic underrepresentation in reference databases emerged as recurring, largely unresolved barriers. A closed-loop framework that pairs multi-omic profiling with functional validation and tiered workforce competencies offers a plausible route toward durable, equitable precision oncology, though prospective, adequately powered trials are still needed to confirm its clinical benefit.

Zitieren

APA

(2026). Integrating Genomics, Transcriptomics, and Organoid-Based Drug Testing for Precision Cancer Care. Integrative Biomedical Research. https://doi.org/10.25163/biomedical.10110907

Vancouver

Integrating Genomics, Transcriptomics, and Organoid-Based Drug Testing for Precision Cancer Care. Integrative Biomedical Research. 2026. doi:10.25163/biomedical.10110907

BibTeX
@article{euvimed2026,
  title = {Integrating Genomics, Transcriptomics, and Organoid-Based Drug Testing for Precision Cancer Care},
  journal = {Integrative Biomedical Research},
  year = {2026},
  doi = {10.25163/biomedical.10110907}
}
Kostenlos starten →